Department of Pharmacy, Wuhan General Hospital of Guangzhou Military Command, Wuhan, PR China.
Beijing Key Laboratory of Drug Delivery Technology and Novel Formulation, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical college, Beijing, PR China.
PLoS One. 2014 Dec 26;9(12):e114835. doi: 10.1371/journal.pone.0114835. eCollection 2014.
The aim of the present work was to study the in vitro/in vivo characteristics of dutasteride loaded biodegradable microspheres designed for sustained release of dutasteride over four weeks. An O/W emulsion-solvent evaporation method was used to incorporate dutasteride, which is of interest in the treatment of benign prostatic hyperplasia (BPH), into poly(lactide-co-glycolide) (PLGA). A response surface method (RSM) with central composite design (CCD) was employed to optimize the formulation variables. A prolonged in vitro drug release profile was observed, with a complete release of the entrapped drug within 28 days. The pharmacokinetics study showed sustained plasma drug concentration-time profile of dutasteride loaded microspheres after subcutaneous injection into rats. The in vitro drug release in rats correlated well with the in vivo pharmacokinetics profile. The pharmacodynamics evaluated by determination of the BPH inhibition in the rat models also showed a prolonged pharmacological response. These results suggest the potential use of dutasteride loaded biodegradable microspheres for the management of BPH over long periods.
本工作旨在研究经皮给药系统中多西他赛载药微球的体外/体内特性,该系统可在四周内持续释放多西他赛,用于治疗良性前列腺增生(BPH)。采用 O/W 乳剂-溶剂挥发法将多西他赛(一种治疗 BPH 的药物)包封到聚乳酸-羟基乙酸共聚物(PLGA)中。采用中心复合设计(CCD)的响应面法(RSM)优化处方变量。结果显示,微球具有延长的体外药物释放曲线,28 天内可完全释放包封的药物。药代动力学研究表明,多西他赛载药微球皮下注射后可在大鼠体内维持稳定的药物浓度-时间曲线。大鼠体内的体外药物释放与药代动力学特征具有良好的相关性。通过测定大鼠模型中 BPH 抑制率评估药效学,也显示出了延长的药理反应。这些结果表明,多西他赛载药可生物降解微球有望用于长期治疗 BPH。